1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1111/pde.13404" target="_blank" rel="noreferrer noopener">http://doi.org/10.1111/pde.13404</a>
Pages
208–212
Issue
2
Volume
35
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
Publisher
An entity responsible for making the resource available
Pediatric dermatology
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
2018-03
Subject
The topic of the resource
Administration; Adolescent; Female; Humans; hyperhidrosis; Hyperhidrosis/*drug therapy; Male; Mandelic Acids/*administration & dosage/adverse effects; oxybutynin; Parasympatholytics/*administration & dosage/adverse effects; pharmacology; Pilot Projects; Prospective Studies; quality of life; Quality of Life; Severity of Illness Index; therapy-topical; Topical; Treatment Outcome; Young Adult
Creator
An entity primarily responsible for making the resource
Nguyen Nicholas V; Gralla Jane; Abbott James; Bruckner Anna L
Description
An account of the resource
BACKGROUND/OBJECTIVES: There are no reliably effective, well-tolerated topical agents for the treatment of hyperhidrosis. We sought to evaluate the efficacy and tolerability of oxybutynin 3% gel in adolescents and young adults with primary focal hyperhidrosis. METHODS: Patients with severe axillary hyperhidrosis were treated with topical oxybutynin 3% gel for 4 weeks. Response to treatment was assessed by calculating change in Hyperhidrosis Disease Severity Score from baseline to weeks 1 and 4. Change in health-related quality of life was assessed using the Children's Dermatology Life Quality Index or the Dermatology Life Quality Index. Adverse effects were evaluated using patient diaries, investigator global review, and physical examination. RESULTS: Of 10 patients aged 13-24 enrolled, seven completed the study. Of those who completed the study, four (57.1%) reported reduction in axillary Hyperhidrosis Disease Severity Score at week 1 and all seven (100%) at week 4. Six patients (85.7%) reported reduction in Children's Dermatology Life Quality Index or Dermatology Life Quality Index score. Anticholinergic adverse effects were infrequent. The majority of treatment-related adverse events were mild to moderate in severity. One patient experienced a severe adverse event. CONCLUSION: Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study. Safety and efficacy should be further evaluated in a large, prospective, placebo-controlled study.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/pde.13404" target="_blank" rel="noreferrer noopener">10.1111/pde.13404</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Abbott James
Administration
Adolescent
Bruckner Anna L
Department of Internal Medicine
Female
Gralla Jane
Humans
hyperhidrosis
Hyperhidrosis/*drug therapy
Male
Mandelic Acids/*administration & dosage/adverse effects
NEOMED College of Medicine
Nguyen Nicholas V
oxybutynin
Parasympatholytics/*administration & dosage/adverse effects
Pediatric dermatology
pharmacology
Pilot Projects
Prospective Studies
Quality of Life
Severity of Illness Index
therapy-topical
Topical
Treatment Outcome
Young Adult